- 회사 소개
AM Sciences was established in 2016 with a goal of developing global new drugs.
AM Sciences is developing the essential therapeutic agent for hepatitis B virus (HBV), which is in need of complete cure.
At the same time, AM Sciences is aiming to become the 'engine' of new drug development. In particular, we are acting as a liaison between global biopharm companies and founders with creative and innovative research results which enables an efficient drug development.
The core members of AM Sciences are composed of researchers with diverse experiences in various fields of drug development.
They have experiences in developing and launching a number of new drugs in the global pharmaceutical industry and also have established a new drug venture company, entering a number of drug candidates into clinical trials. In addition, they have experiences in incubating a venture company in the early stage of establishment, leading to success in technology transfer or M&A.
These experiences in drug development with the global network of our core members will make a great progress by acting synergistically with creative ideas and efforts of AM Sciences researchers in the development of new drugs.
Yeongsik Jung KRICT, Medical chemistry
Subong Han KRICT, Medical chemistry
Woochan Son Asan Medical Centre, Toxicology
Juyeon LEE KRICT, Computer modeling
Seonju Ahn KRICT, ADME
Andy Bader Mirna Therapeutics, Inc., Oncology
KiHang Choi Chemistry Professor at Korea University
Seung-Kew Yoon Catholic University, Seoul St. Mary’s Hospital
Hak Joong Kim Chemistry Professor at Korea University